Table 1.
Patient characteristics
| Rt. Side tumors (n=29) | Lt. side tumors (n=124) | MSS (%) (n=147) | MSI (%) (n=6) | p-value | ||
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 16 (55.2%) | 75 (60.5%) | 0.676 | 89 (60.5) | 2 (33.3) | 0.223 |
| Female | 13 (44.8%) | 49 (39.5%) | 58 (39.5) | 4 (66.7) | ||
| Age, years | ||||||
| ≤ 65 | 19 (65.5%) | 93 (75.0%) | 0.352 | 108 (73.5) | 4 (66.7) | 0.659 |
| 65 < | 10 (34.5%) | 31 (25.0%) | 39 (26.5) | 2 (33.3) | ||
| ECOG performance status | ||||||
| 1 | 29 (100.0%) | 124 (100.0%) | 147 (100.0) | 6 (100.0) | ||
| Primary site | - | - | - | |||
| Left sided colon | - | - | 121 (82.3%) | 3 (50.0%) | 0.082 | |
| Right sided colon | - | - | 26 (17.7%) | 3 (50.0%) | ||
| No. of metastatic sites | ||||||
| 1 | 11 (37.9%) | 61 (49.2%) | 0.307 | 70 (47.6) | 2 (33.3) | 0.685 |
| 1 < | 18 (62.1%) | 63 (50.8%) | 77 (52.4) | 4 (66.7) | ||
| Treatment line including cetuximab | ||||||
| ≤ 2 | 11 (37.9%) | 40 (32.3%) | 0.662 | 48 (32.7) | 3 (50.0) | 0.401 |
| 2 < | 18 (62.1%) | 94 (67.7%) | 99 (67.3) | 3 (50.0) | ||
| KRAS status | ||||||
| Wild | 25 (86.2%) | 115 (92.7%) | 0.271 | 134 (91.2) | 6 (100.0) | 0.664 |
| Mutant | 4 (13.8%) | 9 (7.3%) | 13 (8.8) | 0 (0.0) | ||
| BRAF status | ||||||
| Wild | 10 | 55 | 0.023 | 63 (42.9) | 2 (33.3) | 0.345 |
| Mutant | 4 | 3 | 6 (4.1) | 1 (16.7) | ||
| N.E. | 15 | 66 | 78 (53.1) | 3 (50.0) | ||
| Microsatellite instability (MSI) status | - | - | ||||
| MSI-H | 3 (10.3%) | 3 (2.4%) | 0.079 | - | - | - |
| MSS | 26 (89.7%) | 121 (97.6%) | - | - |